Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.09 USD | -1.59% | +22.13% | +74.58% |
14/05 | Taysha Gene Therapies Q1 Net Loss Narrows, Revenue Declines -- Shares Down After Hours | MT |
14/05 | Transcript : Taysha Gene Therapies, Inc., Q1 2024 Earnings Call, May 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+74.58% | 59Cr | |
+33.63% | 5.08TCr | |
-0.09% | 4.28TCr | |
+49.62% | 4.2TCr | |
-4.96% | 2.95TCr | |
+11.18% | 2.61TCr | |
-21.95% | 1.91TCr | |
+8.61% | 1.31TCr | |
+28.31% | 1.22TCr | |
+24.73% | 1.21TCr |
- Stock Market
- Equities
- TSHA Stock
- News Taysha Gene Therapies, Inc.
- Morgan Stanley Adjusts Taysha Gene Therapies' Price Target to $1 From $3, Keeps Equalweight Rating